Metaplastic carcinoma with chondroid differentiation (MMPC) is a subtype of breast metaplastic carcinoma with mesenchymal differentiation. Although fine-needle aspiration (FNAB) and core-needle biopsy (CNB) are commonly used for the diagnosis of breast cancer, not enough studies proving the diagnostic cost-effectiveness of these techniques for the identification of MMPC have been published so far. The aim of this study was to investigate the concordance between the presurgical diagnosis using FNAB/CNB and the definitive diagnosis in the surgical specimen in pure MMPC. A case of MMPC is also reported. Study Design: All cases of MMPC diagnosed in our institution from 1995 to 2011 were reviewed. The presence of chondroid differentiation in cytological studies or biopsies and the proportion of chondroid matrix in the surgical specimen were evaluated. Results: A total of 13 cases of pure MMPC were collected. The diagnosis was suspected in 25% of FNABs and was rendered in 40% of CNBs. Conclusions: The chondroid component in MMPC is hard to identify by FNAB and CNB. The random distribution and proportion of the chondroid differentiation in the tumour and the expertise in performing the technique and in identifying the chondroid component may play an important role in the diagnosis of MMPC using these techniques.

Keywords:
Breast, Metaplastic carcinoma, Chondroid differentiation , Matrix-producing carcinoma, Fine-needle aspiration biopsy
1.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ: The WHO Classification of Tumors of the Breast, ed 4. Lyon, International Agency for Research on Cancer, 2012.
2.
Wargotz ES, Norris HJ, et al: Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989;20:628-635.
3.
Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ: Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic. Am J Surg Pathol 2009;33:534-541.
4.
Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010;120:627-637.
5.
Gupta RK: Cytodiagnostic patterns of metaplastic breast carcinoma in aspiration samples: a study of 14 cases. Diagn Cytopathol 1999;20:10-12.
6.
Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, Maisonneuve P, Vento AR, Viale G: Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007;101:349-353.
7.
Lieske B, Ravichandran D, Wright D: Role of fine-needle aspiration cytology and core biopsy in the preoperative diagnosis of screen-detected breast carcinoma. Br J Cancer 2006;95:62-66.
8.
Joshi D, Songh P, Zonunfawni Y, Gangane N: Metaplastic carcinoma of the breast: cytological diagnosis and diagnostic pitfalls. Acta Cytol 2011;55:313-318.
9.
Castellà E, Gómez-Plaza MC, Urban A, Llatjós M: Fine-needle aspiration biopsy of metaplastic carcinoma of the breast: report of a case with abundant myxoid ground substance. Diagn Cytopathol 1996;14:325-327.
10.
Bagga PK, Mittal A, Mahajan NC: Matrix-producing carcinoma of the breast: fine needle aspiration cytology findings of a rare subtype of metaplastic carcinoma. Cytopathology 2011;22:421-422.
11.
Lale S, Kure K, Lingamfelter D: Challenges to diagnose metaplastic carcinoma of the breast through cytologic methods: an eight-case series. Diagn Pathol 2011;6:7.
12.
Kuo YL, Chang TW: Can concurrent core biopsy and fine needle aspiration biopsy improve the falser negative rate of sonographically detectable breast lesions? BMC Cancer 2010;10:371.
13.
Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK: Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 2006;59:1079-1083.
14.
Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
15.
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-R1035.
16.
Okada N, Hasebe T, Iwasaki M, Tamura N, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kanai Y, Kinoshita T: Metaplastic carcinoma of the breast. Hum Pathol 2010;41:960-970.
17.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim JH, Kim JS, Nam SJ, Yang JH: The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 2011;126:471-478.
18.
Yamaguchi R, Horii R, Maeda I, Suga S, Makita M, Iwase T, Oguchi M, Ito Y, Akiyama F: Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol 2010;41:679-685.
19.
Shui R, Bi R, Cheng Y, Lu H, Wang J, Yang W: Matrix-producing carcinoma of the breast in the Chinese population: a clinicopathological study of 13 cases. Pathol Int 2011;61:415-422.
20.
Rakha EA, Tan PH, Shaaban A, Tse GM, Esteller FC, van Deurzen CH, Purnell D, Stotter A, Chan T, Yamaguchi R, Dodwell D, Jager A, Soler MT, Juneinah E, Plaza ML, Hodi Z, McCulloch T, Lee AH, Ellis IO: Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast 2013;22:13-18.
21.
Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL Jr, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ: Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 2012;131:41-48.
22.
Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, Lu YS, Cheng AL: Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat 2011;130:345-351.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.